BioCentury | Dec 3, 2019
Financial News

Dec. 2 Financial Quick Takes: Kodiak gains on royalty deal; plus Clover, Aslan, Transcenta, EOC, Hui-Gene and ViGeneron

...an intraday low of $0.35 on Nov. 14. On Monday, Aslan said its IL-13RA1 inhibitor ASLAN004...
BioCentury | Jun 2, 2019
Company News

Aslan’s change of course on eczema asset brings flexibility for future deals

...Aslan's decision to restructure an existing deal with CSL for atopic dermatitis candidate ASLAN004, extending the...
...Aslan's decision to obtain ASLAN004's full rights, Firth said Saturday. Downstream of the receptor that ASLAN004...
...Interleukin-4 receptor; STAT6 - Signal transducer and activator of transcription 6 Paul Bonanos, Assistant Editor ASLAN004, CSL334 Dupixent...
BioCentury | Feb 1, 2019
Product Development

Year of the lion

...does not intend to renegotiate rights to its third clinical candidate, the Phase I compound ASLAN004...
...stage and then partner it with a pharma company.” Aslan expects Phase I data from ASLAN004...
...Ltd. (ASX:CSL), Parkville, Australia Sanofi (Euronext:SAN; NASDAQ:SNY), Paris, France Allison Johnson, Staff Writer ASLAN002, BMS777607, BMS-777607 ASLAN003, LAS186323 ASLAN004, CSL334 varlitinib...
BioCentury | Feb 1, 2019
Company News

Ahead of 2019 milestones, Aslan reduces headcount, operating costs

...AML), and complete a Phase I trial of atopic dermatitis candidate ASLAN004 in healthy volunteers. ASLAN004...
...IL-13 receptor α 1 Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN), Singapore, Singapore Business: Other Allison Johnson ASLAN003, LAS186323 ASLAN004, CSL334 varlitinib...
BioCentury | Jan 29, 2019
Company News

Aslan to reduce headcount, operating costs to support upcoming milestones

...AML), and complete a Phase I trial of atopic dermatitis candidate ASLAN004 in healthy volunteers. ASLAN004...
...NASDAQ. DHODH - dihydroorotate dehydrogenase; IL-13RA1 (IL-13Ra; CD213A1) - IL-13 receptor α 1 Allison Johnson ASLAN003, LAS186323 ASLAN004, CSL334 varlitinib...
BioCentury | May 19, 2014
Finance

Highlights of weekly biotech stock moves

...A17). CSL Ltd. (ASX:CSL) rose A$0.60 to A$69.90 last week after licensing worldwide rights to CSL334...
BioCentury | May 19, 2014
Company News

Aslan, CSL deal

...Aslan gained worldwide rights to CSL334 ( ASLAN004 ) from CSL. The human mAb against IL-13...
...CD213A1 ) is in preclinical testing to treat asthma. Aslan will fund and develop CSL334...
BioCentury | May 14, 2014
Company News

Aslan gains rights to preclinical asthma product from CSL

...Aslan Pharmaceuticals Pte. Ltd. (Singapore) gained worldwide rights to CSL334 from CSL Ltd. (ASX:CSL). The human...
...IL-13RA1; IL-13Ra; CD213A1) is in preclinical testing to treat asthma. Aslan will fund and develop CSL334...
Items per page:
1 - 8 of 8